Activation of innate immunity by prostate specific antigen (PSA)

Prostate

Volumn 66, Issue 15, 2006, Pages 1592-1599

  Kodak, James A ^a   Mann, Dean L ^a   Klyushnenkova, Elena N ^a   Alexander, Richard B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Inflammation; Interferon gamma; Monocytes; Natural killer cells; Prostate specific antigen

Indexed keywords

CD14 ANTIGEN; GAMMA INTERFERON; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL INFILTRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE EPITHELIUM;

CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE II; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MONOCYTES; PROSTATE-SPECIFIC ANTIGEN; PROSTATITIS;

EID: 33750441163     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20414     Document Type: Article

References (23)

1. Lilja H. Biology of prostate-specific antigen. Urology 2003;62 (5, Supplement 1):27-33.
2. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76(5):1899-1903.
3. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57(15):3111-3114.
4. Lilja H, Cockett AT, Abrahamsson PA. Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer 1992;70(1 Suppl):230-234.
5. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi, MS. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50(5):710-714.
6. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 1999;84(4):470-474.
7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros, JA, Andriole G. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156-1161.
8. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80(2):281-285.
9. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12(1):29-38.
10. Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN. Prostate specific antigen inhibits immune responses in vitro: A potential role in prostate cancer. J Urol 2002;168(2):741-747.
11. Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin G. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 2003;170(5): 2026-2030.
12. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5(2):112-124.
13. Macaluso M, Lawson L, Akers R, Valappil T, Hammond K, Blackwell R, Mortin. Prostate-specific antigen in vaginal fluid as a biologic marker of condom failure. Contraception 1999;59(3): 195-201.
14. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urology 1979;121:755-760.
15. Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol 2000;163(1):131-136.
16. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155(6):1985-1992.
17. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171(2 Pt 2):S36-S40.
18. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
19. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 1999;53(3 Suppl 3a):29-39.
20. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Steiner. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66(1):96-107.
21. Steiner GE, Gessl A, Kramer G, Schollhammer A, Forster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994;151(2):480-484.
22. Olsson AY, Lilja H, Lundwall A. Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen. Genomics 2004;84(1):147-156.
23. Olsson AY, Valtonen-Andre C, Lilja H, Lundwall A. The evolution of the glandular kallikrein locus: Identification of orthologs and pseudogenes in the cotton-top tamarin. Gene 2004;343(2):347-355.